Pricing Log in Create free account
Friday 6 November 2026 Export FOCL’s income statement to Excel — free account

FocalTherics

FOCL Healthcare Medical Distribution

Revenue
+38.9%
EPS
−129.4%
Free cash flow
+21.5%
Total debt
+366.8%

Quarter to June 2026, against a year earlier

3.85 0.40 −9.41%
Market cap
$159.3M
P/E
0.0×
Fwd P/E
−3.7×
Dividend yield
—
F-score
3/9
Altman Z
−0.87
Beneish M
−3.14
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.59
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — 1 — — 8 — — —
Sell — — — — — — — — — — — —
Insider Ownership 0.66%

Capital & Financial Ratios $m

Size
Market Cap 159.29
Revenue ttm 77.77
Net income ttm (38.97)
Free cash flow ttm (19.13)
Net debt Q 18.55
Valuation
P/E 0.00
Forward P/E (3.69) (negative: loss-making)
Price / sales 2.01
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.00
Financial health
Current ratio Q 1.60 (at or above 1.5: strong)
Debt / equity Q (12.43) (negative: negative equity)
Interest coverage Q (15.91)
Growth
Revenue growth Q +38.85% (above 0%: growing)
Operating income growth Q −21.29% (below 0%: shrinking)
EPS, this year −33.08% (below 0%: weak)
EPS, next year A +24.06% (at or above 15%: strong)
Revenue, next year A −26.27% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +7.02%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.3×, against a ten-year median of 2.1×; over the ten years it ranged from 0.7× in 2025 to 5.9× in 2023.
P/S against its own 10 years 33.04%
10-year low 10-year high
EV/Sales against its own 10 years 54.16%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 47 31 20 22
Receivables 21 21 23 11
Inventory 16 19 13 8
Other 1 1 1 2
85 73 57 59
2023 2024 2025 Q'26
Payables 12 13 12 10
ST’ Debt 4 9 8 3
Other 2 2 2 6
30 39 37 37

Compound Annual Growth %

10y 5y 3y
Sales 7.01% 8.18% 6.70%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 1.94% (8.33%) (36.40%)

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.20 Actual −0.24

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 −0.20 −0.24 Miss by 0.04
Q3 FY26 −0.18 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.24) (0.39) — — —
’25 (0.20) (0.17) (0.15) (0.25) (0.78)
’24 (0.13) (0.18) (0.19) (0.05) (0.55)
’23 (0.22) (0.14) (0.12) (0.15) (0.62)
’22 0.01 0.06 0.00 (0.14) (0.09)
’21 0.03 (0.02) (0.04) 0.04 0.02
’20 (0.05) (0.01) (0.04) 0.03 (0.07)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 18 13 — — —
’25 14 10 16 31 71
’24 16 17 14 22 69
’23 16 16 13 21 65
’22 15 15 12 16 58
’21 12 12 11 16 52
’20 8 10 11 18 48
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (4) — — —
’25 (5) (5) (4) (2) (16)
’24 (4) (7) (4) 0 (15)
’23 (3) (6) (2) (5) (16)
’22 1 0 2 (7) (3)
’21 2 (1) 1 3 5
’20 — — (2) 5 2
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (4) (5) — — —
’25 (7) (6) (6) (4) (22)
’24 (5) (7) (6) 0 (19)
’23 (5) (8) (3) (6) (21)
’22 0 0 2 (8) (6)
’21 1 (1) 1 2 3
’20 — — (4) 4 0
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 39 40 46 50 48 52 58 65 69 71 78 +6.7% 52 70 88 +7.7%
Gross margin, % 46.08 41.43 43.18 46.76 44.11 41.81 43.90 40.40 41.42 42.54 44.53 (3.5) pt
EBT 5 0 0 2 (1) 1 (2) (22) (20) (29) (39) n/m
EBT margin, % 12.48 (0.82) 0.05 4.88 (2.85) 2.03 (3.80) (33.98) (29.21) (40.85) (49.52) (53.3) pt
Net income 4 (1) 0 2 (2) 1 (3) (23) (21) (29) (39) n/m
Per share, $
Per share, $ Revenue 1.42 1.40 1.60 1.73 1.63 1.62 1.69 1.77 1.86 1.88 2.07 +3.2%
Earnings 0.15 (0.02) (0.01) 0.06 (0.07) 0.02 (0.09) (0.62) (0.55) (0.78) (1.03) n/m
Cash flow 0.04 (0.12) 0.01 0.15 0.08 0.16 (0.09) (0.43) (0.39) (0.44) (0.35) n/m
Capex (0.05) (0.06) (0.08) (0.06) (0.08) (0.06) (0.07) (0.13) (0.12) (0.15) (0.16) +14.2%
Free cash flow 0.00 (0.18) (0.07) 0.09 0.00 0.10 (0.16) (0.56) (0.51) (0.59) (0.51) +86.2%
Book value 0.97 0.98 1.02 1.06 1.03 1.84 2.19 1.67 1.14 0.52 (0.09) (6.7%)
Shares, m 28 29 29 29 29 32 34 37 37 37 37 +3.4%
Valuation, ×
Valuation, × P/E 20.88 0.00 0.00 84.70 0.00 247.52 0.00 0.00 0.00 0.00 0.00 35.3
P/S 2.36 2.05 1.16 2.56 3.17 3.69 6.18 3.00 1.19 1.75 2.01 2.7
P/B 3.43 2.91 1.82 4.20 4.69 3.38 4.70 3.19 1.94 6.35 0.00 3.7
EV/Sales 1.92 1.64 0.83 2.21 2.67 2.84 5.12 2.37 0.91 1.78 2.25 2.2
EV/FCF 29.78 (7.76) (2.96) (17.71) 97.13 56.22 (50.43) (7.40) (3.15) (5.40) (9.15) 8.8
Cash, $m
Cash, $m Operating cash flow 1 (3) 0 4 2 5 (3) (16) (15) (16) (13) n/m
Capex (1) (2) (2) (2) (2) (2) (2) (5) (4) (6) (6) +18.0%
Free cash flow 0 (5) (2) 3 0 3 (6) (21) (19) (22) (19) +92.2%
Balance, $m
Balance, $m Working capital 28 26 28 28 27 58 72 55 33 20 22 (3.7%)
Net debt (17) (17) (15) (17) (18) (46) (59) (40) (19) 4 19 n/m
Shareholders’ equity 27 28 29 31 30 59 75 62 42 19 (3) (3.6%)
Returns, %
Returns, % ROA 9.01 (1.47) (0.72) 2.89 (3.18) 1.07 (3.12) (22.29) (21.84) (34.73) (50.28) (43.7) pt
ROIC 2.74 (12.11) (6.92) 11.41 1.61 (9.18) (16.79) (62.22) (60.16) (66.17) (110.75) (68.9) pt
ROE 19.74 (2.77) (1.38) 5.63 (6.42) 1.86 (4.59) (33.44) (39.55) (94.50) (133.48) (114.2) pt
People
People Employees 197 200 215 216 223 227 264 307 310 289 — +4.3%
Revenue/emp, $m 0.20 0.20 0.22 0.23 0.21 0.23 0.22 0.21 0.22 0.24 — +2.2%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

FocalTherics vs peers in Medical Distribution (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
HSIC Henry Schein, Inc. $9.4B 22.8× 21.3× +3.95% (above 0%: growing) +34.81% (above 0%: growing) −7.09% (below 0%: shrinking) 31.84% 5.56% Compare
AHG Akso Health Group Sponsored ADR $1.1B — (loss-making) — (loss-making) +263.89% (above 0%: growing) n/m −12,975.04% (below 0%: shrinking) 0.00% 0.00% Compare
FOCL FocalTherics $159.3M — (loss-making) — (loss-making) +38.85% (above 0%: growing) n/m +21.49% (above 0%: growing) 55.59% (60.83%)
COSM Cosmos Health Inc. $29.2M — (loss-making) — (loss-making) +28.76% (above 0%: growing) n/m +9.39% (above 0%: growing) 7.96% (15.41%) Compare
ACH Accendra Health, Inc. $23.0M — (loss-making) — (loss-making) −10.07% (below 0%: shrinking) n/m −1,624.82% (below 0%: shrinking) 42.95% (5.73%) Compare
YI 111, Inc. Sponsored ADR $15.5M — (loss-making) — (loss-making) −29.61% (below 0%: shrinking) n/m −185.70% (below 0%: shrinking) 5.33% (0.85%) Compare
MEDS DataMeds AI, Inc $5.5M — (loss-making) — −77.15% (below 0%: shrinking) n/m −41.85% (below 0%: shrinking) 10.24% (412.67%) Compare
HKPD Cellyan Biotechnology Co., Ltd $3.4M — — — — −90.45% (below 0%: shrinking) — — Compare
SNYRQ Synergy CHC Corp. $1.3M — (loss-making) 1.6× −32.77% (below 0%: shrinking) n/m −148.51% (below 0%: shrinking) 72.29% (10.32%) Compare
Median of peers $19.2M — — −10.07% — −119.48% 10.24% (5.73%)

All 12 Medical Distribution stocks →

Pay and ownership Proxy statement filed 14 May 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 1.74m 2.66m 62.31
2024 1.28m 768.59k 41.86

Ownership

Directors and executive officers, together 10.10%
Soleus Private Equity Fund II, L.P. 19.50%
Morgan Stanley 8.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

FocalTherics (FOCL) Latest News

6 Nov

Impact 4 ·
Impact 3 · · MarketBeat transcript
Impact 3 · · GuruFocus.com

5 Nov

Impact 3 · · GlobeNewswire

22 Oct

Impact 3 · · GlobeNewswire

14 Aug

Impact 4 ·

13 Aug

Impact 3 · · MarketBeat transcript

11 Aug

Impact 3 ·
Impact 3 ·
Impact 3 ·

30 Jun

Impact 4 ·

16 Jun

Impact 3 ·

1 Jun

Impact 4 · · MarketBeat
Impact 3 · · The Motley Fool transcript

29 May

Impact 3 · · GlobeNewswire

14 May

Impact 4 · · GlobeNewswire

7 May

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

30 Apr

Impact 4 · · GlobeNewswire

25 Mar

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire
Impact 3 · · GuruFocus.com

19 Mar

Impact 4 · · MarketBeat

12 Feb

Impact 3 · · GlobeNewswire

9 Feb

Impact 3 · · MT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT NewswiresMT Newswires

17 Jan

Impact 3 · · Simply Wall St.

12 Jan

Impact 4 · · GlobeNewswire

5 Dec

Impact 3 · · MT Newswires

20 Nov

Impact 4 · · GlobeNewswireGuruFocus.comMedical Device NetworkMedTech DiveMedical Device NetworkZacksMedical Device NetworkMT Newswires

18 Nov

Impact 3 · · GlobeNewswireMedical Device NetworkGuruFocus.comInsider Monkey
stockrow.com/FOCL · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com